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Abstract
Introduction: Sarcomatoid carcinoma of the urinary bladder is a rare bidirectional malignant neoplasm with
epithelial and mesenchymal differentiation. The epithelial component is mainly high-grade urothelial carcinoma,
and the mesenchymal component includes rhabdomyosarcoma. However, proper differential diagnosis of adult
rhabdomyosarcomatous tumors of the bladder can be a challenge. Moreover, low-grade urothelial carcinoma as
the epithelial component of sarcomatoid carcinoma has not been reported.
Case presentation: A 64-year-old Asian man with a history of transurethral resection of low-grade urothelial
carcinoma of the bladder visited our department with complaints of frequent urination and macroscopic hematuria.
Computed tomography and magnetic resonance imaging demonstrated a large mass located in the anterior wall
of the bladder. Pathological diagnosis of transurethral biopsy was low-grade, non-invasive papillary urothelial
carcinoma, and tumor tissue was removed by total cystectomy. Immunohistochemical studies and fluorescence in
situ hybridization assay of the resected neoplastic tissue revealed extensive rhabdomyosarcomatous differentiation
causing the formation of a large pedunculated polyp with a papillary appearance of recurrent low-grade urothelial
carcinoma. No evidence of recurrence was detected during 2 years of follow-up without further treatment.
Conclusions: Urothelial carcinoma of the urinary bladder with extensive rhabdomyosarcomatous differentiation is
rare, but it should be considered in the differential diagnosis even when urothelial carcinoma coexisting with a
rhabdomyosarcomatous component is low-grade and non-invasive.
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Introduction
Sarcomatoid carcinoma (SC) is a rare bidirectional
malignant neoplasm with epithelial and mesenchymal
differentiation that accounts for less than 0.3% of all
histological subtypes of primary urinary bladder tumors
[1, 2]. The epithelial component is mainly high-grade
urothelial carcinoma (UC), and the mesenchymal malig-
nant component consists of osteosarcoma, chondros
arcoma, rhabdomyosarcoma (RMS), and so forth [1]. In-
flammatory myofibroblastic tumor (IMT), also referred to
as inflammatory pseudotumor, pseudosarcomatous fibro-
myxoid tumor, and post-operative spindle cell nodule, is an
unusual, benign, myofibroblastic spindle cell lesion that
can arise from various organs, including the urinary
bladder. IMT of the bladder manifests prominent
nucleoli, mitoses, chromosomal abnormalities, necrosis,
and muscularis propria invasion, resembling malignant
spindle cell tumors, including pure RMS, leiomyosarcoma,
and SC [3, 4].
Clinically, proper differential diagnosis of adult rhab-
domyosarcomatous tumors of the urinary bladder,
including pure RMS, SC, and IMT, can be a challenge.
In this report, we present a case of recurrent low-grade
UC with extensive rhabdomyosarcomatous differenti-
ation in an elderly man. The lesion presented as a large
mass due to a rhabdomyosarcomatous component at the
first medical examination. To the best of our knowledge,
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this is the first reported case of low-grade UC as the
epithelial component of SC.
Case presentation
A 52-year-old Asian man underwent transurethral resec-
tion (TUR) of stage I (T1N0M0) low-grade UC (transi-
tional cell carcinoma [TCC]) in the anterior wall of the
bladder at a nearby hospital. He was referred to our hos-
pital 4 months after undergoing TUR. Cytoscopic exam-
ination performed at our division showed scar formation
after TUR with negative biopsies, and he did not wish to
undergo further treatment. Although we planned follow-
up studies, he stopped visiting our hospital just after the
cytoscopic examination. At the age of 64, 12 years after
undergoing TUR, he visited our department with com-
plaints of frequent urination and macroscopic hematuria
without painful micturition. During his physical exa-
mination, a pelvic mass and superficial lymph nodes
were not palpable, but computed tomography (CT) and
magnetic resonance imaging (MRI) demonstrated a large
mass (3.8cm×2.9cm) with infiltration into the muscle
layer (T2b), which was located in the anterior wall of the
urinary bladder. The mass intensity was the same as in
the rest of the bladder wall on T1-weighted images
and slightly greater than in the bladder wall on T2-
weighted ones (Fig. 1a, b). Urinary cytology was positive
and suggestive of UC (TCC). Cytoscopic examination
revealed a large pedunculated polyp with a surrounding
papillary appearance. The patient subsequently underwent
a transurethral biopsy of the tumor. The pathological
diagnosis was low-grade, non-invasive papillary UC (Ta),
and there was no evidence of metastasis on CT or MRI.
Although muscularis propria invasion was not observed in
the transurethral biopsy specimens, the patient was diag-
nosed with stage II (T2bN0M0) UC on the basis of MRI
findings of tumor infiltration into the muscle layer. There-
fore, tumor tissue was removed by total cystectomy
(Fig. 1c), and bilateral pelvic lymph node dissection of
external iliac and obturator regions with ileal conduit
urinary diversion was performed. In total, eight lymph
nodes were dissected. No post-operative complications
were observed.
The final diagnosis of low-grade UC (TCC) with rhab-
domyosarcomatous differentiation (INFa, pTa [epithelial
component]/pT2b [mesenchymal component], LVI0,
RM0, u-rt0, u-lt0, ur0, N0, M0) was established on the
basis of immunohistochemical studies and fluorescence in
situ hybridization (FISH) assay of the resected neoplastic
tissue. The pedunculated polyp was made up mainly of a
sarcomatous component with a spindle cell–like appea-
rance, which was characterized by severe nuclear pleo-
morphism and mitotic activity (Fig. 2a), and scattered
areas of necrosis. Some strap- and racket-shaped cells with
eosinophilic elongated cytoplasm were present in a dis-
persed manner (Fig. 2a). Spindle-like cells were positive
for vimentin (Fig. 2b), myogenin, and desmin, suggesting
rhabdomyosarcomatous differentiation. In contrast, these
cells were negative for cytokeratins recognized by AE1/
Fig. 1 Magnetic resonance imaging scans obtained at presentation (a and b) and of the resected urinary bladder (c). Magnetic resonance imaging
demonstrated a large mass (3.8cm×2.9cm) with fragmentation of muscularis propria (arrows), which was located in the anterior wall of the urinary
bladder. The mass intensity was the same as in the rest of the bladder wall on T1-weighted images (a) and slightly greater than in the bladder wall
on T2-weighted ones (b). The resected urinary bladder showed a large pedunculated polyp with a surrounding papillary appearance
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AE3 (Fig. 2c), chromogranin, synaptophysin, α-smooth
muscle actin, and anaplastic lymphoma kinase (ALK)
(Fig. 2d). Rearrangements and copy number gain of the
ALK gene were not detected by FISH (Fig. 2e). Muscularis
propria invasion (T2b) was observed in the sarcomatous
lesion without lymph node metastasis. The epithelial
component of the tumor, which was consistent with a
papillary lesion surrounding the pedunculated polyp,
was low-grade, non-invasive UC (TCC) without necrosis
(Fig. 2f). The rate of positivity of urinary cytology in
patients with low-grade UC (TCC) is about 25% at our in-
stitute. The status of X chromosome inactivation and loss
of heterozygosity (LOH) in both the carcinomatous and
sarcomatous components was not analyzed. No evidence
of recurrence was detected by whole-body CT during
a 2-year follow-up period without further treatment.
Discussion
In our patient, transurethral biopsy revealed UC but not a
sarcomatous component, owing to inadequate sampling.
However, the reverse situation has been reported by
others. Depending on the circumstances, a small focus of
carcinomatous component may be detectable only by ex-
tensive, multiple sampling. Therefore, in the case of adult
rhabdomyosarcomatous tumor, the diagnosis of pure RMS
should be made very carefully [5].
The other difficulty is differentiating this case from
IMT. Although both epithelial and myogenic markers can
be expressed in IMT, a morphologically typical epithelial
component is not interwoven with IMT [4, 6]. Moreover,
recent studies have shown that the majority of IMT
express ALK protein, and FISH analysis has identified
ALK gene alterations within myofibroblastic spindle cells
of IMT, suggesting an etiology of a low-grade mesenchy-
mal neoplasm other than primary inflammatory reaction
[3, 4, 6]. However, our patient’s tumor was a typical
epithelial carcinoma, and ALK protein expression and
ALK alterations of the rhabdomyosarcomatous compo-
nent were both negative.
The accurate histogenesis of SC has not been clarified
in detail. Although multiclonal theory and monoclonal
theory have been discussed, molecular and genetic
research using LOH, comparative genomic hybridization,
and X chromosome inactivation analysis substantiate a
common origin with divergent differentiation [7]. Previous
studies have suggested that the epithelial component of
SC of the bladder precedes the mesenchymal component
[8]. The tumor in our patient may initially have exhibited
Fig. 2 Pathological specimens of the resected neoplastic tissue. a–e Pedunculated polyp. f Papillary lesion. a, f Hematoxylin and eosin staining.
b–d Immunohistochemical staining. e Fluorescence in situ hybridization using a dual-color break-apart probe for anaplastic lymphoma kinase.
The 5′ end of the ALK gene was labeled with Vysis SpectrumGreen, and its 3′ end was labeled with Vysis SpectrumOrange (Abbott Molecular, Des
Plaines, IL, USA). The pedunculated polyp consisted mainly of a sarcomatous component with a spindle cell–like appearance, which was characterized
by severe nuclear pleomorphism and mitotic activity. Some strap- and racket-shaped cells with eosinophilic elongated cytoplasm were
present in a dispersed manner (a). Spindle-like cells were positive for vimentin (b) but negative for cytokeratins recognized by AE1/AE3
(c) and anaplastic lymphoma kinase (d). Rearrangements and copy number gain of the ALK gene were not detected by fluorescence in
situ hybridization. A total of 94% of tumor cells showed pseudo-color signals (yellow color, arrowheads) without deletion of red signals (e).
The papillary lesion was a low-grade, non-invasive urothelial carcinoma without necrosis (f)
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epithelial differentiation as UC and then mesenchymal
differentiation with the appearance of RMS. However, it is
not clear whether the origin of the tumor was residual
cancer cells after TUR or de novo generation.
In most reported cases, the epithelial component of
SC of the bladder is high-grade UC [9, 10]. To the best
of our knowledge, low-grade UC as the epithelial com-
ponent of SC has not been reported before for the
present case. At times, SC occurs in patients who have
undergone chemotherapy, radiotherapy, or a situation in
which cell replication error was induced. However, our
patient had not received any anti-cancer treatment ex-
cept for TUR of low-grade UC. It has been reported that
past history of non-invasive cancer correlates with the
malignant grade in secondary UC [11]. In addition, the
role of inflammation in urothelial cell carcinogenesis has
lately been receiving considerable attention [12]. Inflam-
mation caused by TUR for low-grade UC might have
influenced the mesenchymal differentiation in UC of our
patient. Indeed, others reported two cases of SC with a
history of recurrent bladder cancer and subsequent TUR
[10], although their report and the case of our patient do
not refute the safety of TUR.
Owing to the extreme rarity of SC of the bladder and
the absence of randomized controlled studies, the stand-
ard treatment for SC of the bladder has not been defined.
SC usually presents at a higher T stage with more frequent
regional metastases than UC [13]. Therefore, radical
cystectomy seems to be preferable even in superficial
disease. Although total cystectomy followed by radio-
therapy or chemotherapy has been recommended by
some groups [14, 15], the therapeutic efficacy of these
treatments is still controversial owing to the varying
results. Because muscularis propria invasion was ob-
served in the sarcomatous lesion in our patient, we
considered systemic chemotherapy (e.g., cisplatin plus
gemcitabine regimen) as a treatment option. However,
our patient did not wish to undergo adjuvant treat-
ments after the total cystectomy. Nevertheless, no evi-
dence of recurrence was detected during a 2-year
follow-up period.
Conclusions
UC of the urinary bladder with extensive rhabdomyo-
sarcomatous differentiation is rare, but it should be
considered in the differential diagnosis even when UC
coexisting with a rhabdomyosarcomatous component
is of low grade, especially in cases of a tumor that is
unexpectedly large for low-grade UC. More molecular
biological research is needed to obtain insight into
the pathogenic factors involved in rhabdomyosarco-
matous differentiation in UC to improve the manage-
ment of this disease.
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